

20 **Author Involvement:** All authors had access to the data, a role in writing, reviewing, and
21 approving the manuscript.

22 **Abstract**

23 **Background:** The importance of ambulatory hypoxia without resting hypoxia in COVID-19 is
24 unknown. Ambulatory hypoxia without resting hypoxia may help objectively identify high-risk
25 patients hospitalized with COVID-19. Interventions may be initiated earlier with sufficient lead-
26 time between development of ambulatory hypoxia and other outcome measures.

27 **Methods:** We performed a retrospective study of adult patients hospitalized with COVID-19
28 from March 1, 2020 to October 30, 2020 in ten hospitals in an integrated academic medical
29 system in the Chicagoland area. We analyzed patients who had daily ambulatory oximetry
30 measurements, excluding patients who had first ambulatory oximetry measurements after the use
31 of oxygen therapies (nasal cannula or advanced oxygen therapies). We determined the
32 association of ambulatory hypoxia without resting hypoxia with the eventual need for nasal
33 cannula or advanced oxygen therapies (defined as high flow nasal cannula, Bi-PAP, ventilator, or
34 extracorporeal membrane oxygenation). We also calculated the time between development of
35 ambulatory hypoxia and the need for oxygen therapies.

36 **Results:** Of 531 patients included in the study, 132 (24.9%) had ambulatory hypoxia. Presence
37 of ambulatory hypoxia was strongly associated with subsequent use of nasal cannula (OR 4.8,
38 95% CI 2.8 – 8.4) and advanced oxygen therapy (IRR 7.7, 95% CI 3.4 – 17.5). Ambulatory
39 hypoxia preceded nasal cannula use by a median 12.5 hours [IQR 3.25, 29.25] and advanced
40 oxygenation therapies by 54 hours [IQR 25, 82].

41 **Conclusion:** Ambulatory hypoxia without resting hypoxia may serve as an early, non-invasive
42 physiologic marker for the likelihood of developing moderate to severe COVID-19 and help
43 clinicians triage patients and initiate earlier interventions.

44 **Introduction**

45 Coronavirus-induced-disease-2019 (COVID-19) has caused a pandemic with 56,178,674
46 cases and 1,348,348 deaths worldwide.¹ In our experience, we noted many inpatients with
47 COVID-19 first exhibit hypoxia with exertion, then subsequently develop moderate to severe
48 disease requiring nasal cannula or more advanced oxygen therapies. Early COVID-19 induces
49 occult lung damage, noted by peripheral ground-glass opacities on imaging.² We suspect patients
50 at this stage exhibit ambulatory but not resting hypoxia. Several studies have characterized risk
51 factors for severe COVID-19 based on patient-specific comorbidities and laboratory data. To our
52 knowledge, no study has evaluated ambulatory hypoxia in absence of resting hypoxia as a risk
53 factor for development of moderate to severe disease. Therefore, we aimed to evaluate if
54 ambulatory hypoxia is associated with COVID-19 progression.

55 **Methods**

56 We performed a retrospective observational study of adults (age ≥ 18 years) hospitalized
57 with COVID-19 who had ambulatory oxygen measurements (without first developing resting
58 hypoxia) at Northwestern Medicine (NM) between March 1, 2020 and October 30, 2020. NM is
59 an integrated academic medical system in the Chicagoland area with 10 affiliated hospitals. We
60 compared the associations between patients with and without ambulatory hypoxia and the use of
61 nasal cannula (NC) or advanced oxygenation therapy [defined as high flow nasal cannula
62 (HFNC), bi-level positive airway pressure (BiPAP), mechanical ventilation (vent) or
63 extracorporeal membrane oxygenation (ECMO)]. We evaluated the time from the measurement
64 of ambulatory hypoxia to initiation of NC and advanced oxygenation therapies. This study was
65 approved by the Northwestern University Institutional Review Board.

66 *Procedure*

67 We queried the Northwestern University Enterprise Data Warehouse (EDW) for all adult
68 patients hospitalized with COVID-19 (ICD-10 code) who had ambulatory oxygen levels
69 measured. The EDW is a complete database of clinical data extracted from the electronic
70 medical records at NM. Hospital protocols within NM recommend that all patients with COVID-
71 19 have once daily ambulatory oximetry screening, if able to participate. Any ambulatory
72 oxygen saturation below 90% was considered hypoxia. Oxygen therapy outcomes included need
73 for NC, HFNC, BiPAP, vent, and ECMO. Date and time of ambulatory hypoxia and initiation of
74 all oxygen therapy outcomes were recorded. We *excluded* patients in whom oxygen therapy
75 outcomes occurred before first ambulatory pulse oximetry measurement and those still
76 hospitalized at the end of the study period.

77 Patient demographic and clinical data on admission including age, sex, race and ethnicity,
78 body mass index (BMI), D-dimer, ferritin, and c-reactive protein (CRP) were recorded. The
79 EDW query also included all ICD-10 codes for pre-existing chronic conditions. The Charlson
80 comorbidity index for each patient was calculated based on admission ICD-10 codes to account
81 for severity of illness at admission. For patients with multiple admissions, only data and
82 outcomes during a chronologically first ‘index’ encounter were evaluated. Age, BMI, Charlson,
83 D-dimer, CRP, and ferritin values were categorized for ease of interpretation. Time between
84 ambulatory hypoxia and use of NC or advanced oxygen therapies was measured using the first
85 occurrence of the oxygen therapy outcome.

86 *Analysis*

87 Chi-square tests were used to evaluate bivariate associations between demographic and
88 clinical variables and the proportion of patients with ambulatory hypoxia and subsequent use of
89 nasal cannula or advanced oxygenation therapy. We used multiple logistic regression of the
90 likelihood of nasal cannula to test the significance of ambulatory hypoxia because NC occurred
91 in 13% of patients. We used multiple Poisson regression of the likelihood of advanced oxygen
92 therapy to test the significance of ambulatory hypoxia because advanced oxygenation occurred in
93 6% of patients.^{3,4} We controlled for patients' demographic and clinical characteristics including
94 age, sex, race and ethnicity, BMI, and Charlson score, plus laboratory values that were
95 significant at $p < 0.1$ in bivariate associations. We performed sensitivity analyses substituting
96 specific ICD-10 diagnoses including atrial fibrillation, coronary artery disease, congestive heart
97 failure, diabetes mellitus, connective tissue disease, chronic obstructive pulmonary disease,
98 hepatic failure with encephalopathy, human immunodeficiency virus, hypertension, leukemia or
99 lymphoma, other immunodeficiencies, peripheral arterial disease, renal disease, solid tumor, and
100 transplant in place of the Charlson score. R (3.6.1, Vienna, Austria) was used for analysis.

101 **Results**

102 Our study included 531 patients with ambulatory oximetry measurements prior to
103 oxygenation outcomes. Of these, 132 patients (24.9%) had ambulatory hypoxia. NC was required
104 by 28.8% of patients with ambulatory hypoxia, compared to 8.0% of patients without it
105 ($p = 2.4 \times 10^{-9}$). Advanced oxygenation therapy was required by 18.9% of patients with ambulatory
106 hypoxia, compared to 2.3% without it ($p = 4.6 \times 10^{-11}$). Demographic and clinical variables are
107 listed in Table 1.

108 Multiple logistic and Poisson regression results confirmed that the presence of
109 ambulatory hypoxia was strongly associated with the likelihood of using NC (OR 4.8, 95% CI

110 2.8 – 8.4) and advanced oxygenation (IRR 7.7, 95% CI 3.4 – 17.5); Table 2. Results were
111 unchanged in the sensitivity analysis. Ambulatory hypoxia preceded NC use by a median 12.5
112 hours [IQR 3.25, 29.25] and advanced oxygenation therapies by 54 hours [IQR 25, 82].

113 **Discussion**

114 Our study shows that the presence of ambulatory hypoxia in absence of resting hypoxia is
115 strongly associated with the subsequent development of moderate to severe COVID-19. In our
116 patient population, ambulatory hypoxia occurred several hours before the need for NC and
117 advanced oxygen therapies. This is important because it may enable clinicians to start therapeutic
118 treatments such as remdesivir⁵ and/or dexamethasone⁶ earlier. It may also help health systems
119 effectively identify patients most likely to require ICU-level care, which may improve hospital
120 throughput especially when hospitals are near or at capacity.

121 Ambulatory oximetry has been used to help determine severity of cardiopulmonary
122 diseases including heart failure,⁷ pulmonary hypertension,⁸ chronic obstructive pulmonary
123 disease,⁹ and interstitial lung disease.¹⁰ To our knowledge, the presence of ambulatory hypoxia
124 has never been shown to acutely predict cardiopulmonary disease progression. Recently, some
125 authors have advocated for ambulatory oximetry measurements to evaluate patients for discharge
126 readiness after resolution of COVID-19 symptoms,¹¹ a strategy already adopted in our hospital.
127 We present the first study showing that ambulatory hypoxia predicts worsening pulmonary
128 disease in patients with COVID-19.

129 Our study has several limitations. First our study was performed at one health network
130 with a relatively small number of patients potentially limiting generalizability. However, the
131 associations between ambulatory hypoxia and worsening oxygenation were statistically very

132 strong. Second, we excluded patients who did not have ambulatory oximetry measurements.
133 Ambulatory oxygen measurement is part of the admission order protocols in our health system,
134 so patients without measurements likely represented a sicker cohort unable to ambulate or those
135 discharged quickly. Patients without measurement may also have been cared for by clinicians
136 who did not order ambulatory oximetry, given lacking evidence. Third, we did not directly
137 measure the presence of resting hypoxia because it was often not documented in the medical
138 record before the use of oxygen therapy. The use of oxygen therapy was used as a surrogate for
139 resting hypoxia. Finally, we excluded all patients who used oxygen therapy before ambulatory
140 oximetry measures. These patients likely underwent ambulatory oximetry to determine discharge
141 readiness. Alternatively, there may have been a small number of these patients who were given
142 NC treatment for subjective comfort without resting hypoxia, who then developed ambulatory
143 hypoxia.

144 Future randomized studies should be performed to evaluate earlier interventions in
145 patients with COVID-19 and ambulatory hypoxia without resting hypoxia. An important
146 extension of our findings could be the use of ambulatory oximetry measurement in triaging both
147 outpatients and inpatients with COVID-19. Ambulatory hypoxia may help determine whether
148 admission and inpatient monitoring with continuous pulse oximetry is warranted.

149

150

151

152 **References**

- 153 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet*
154 *Infect Dis* 2020;20(5):533-34. doi: 10.1016/S1473-3099(20)30120-1 [published Online First:
155 2020/02/23]
- 156 2. Wang Y, Dong C, Hu Y, et al. Temporal Changes of CT Findings in 90 Patients with COVID-19
157 Pneumonia: A Longitudinal Study. *Radiology* 2020;296(2):E55-E64. doi:
158 10.1148/radiol.2020200843 [published Online First: 2020/03/20]
- 159 3. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of
160 common outcomes. *JAMA* 1998;280(19):1690-1. doi: 10.1001/jama.280.19.1690 [published
161 Online First: 1998/12/01]
- 162 4. Zou G. A modified poisson regression approach to prospective studies with binary data. *Am J*
163 *Epidemiol* 2004;159(7):702-6. doi: 10.1093/aje/kwh090 [published Online First: 2004/03/23]
- 164 5. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. *N*
165 *Engl J Med* 2020;383(19):1813-26. doi: 10.1056/NEJMoa2007764 [published Online First:
166 2020/05/24]
- 167 6. Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary
168 Report. *N Engl J Med* 2020 doi: 10.1056/NEJMoa2021436 [published Online First: 2020/07/18]
- 169 7. Gheorghiade M, Follath F, Ponikowski P, et al. Assessing and grading congestion in acute heart failure:
170 a scientific statement from the acute heart failure committee of the heart failure association of
171 the European Society of Cardiology and endorsed by the European Society of Intensive Care
172 Medicine. *Eur J Heart Fail* 2010;12(5):423-33. doi: 10.1093/eurjhf/hfq045 [published Online
173 First: 2010/04/01]
- 174 8. Rubin LJ. The 6-minute walk test in pulmonary arterial hypertension: how far is enough? *Am J Respir*
175 *Crit Care Med* 2012;186(5):396-7. doi: 10.1164/rccm.201206-1137ED [published Online First:
176 2012/09/04]
- 177 9. Stoller JK, Panos RJ, Krachman S, et al. Oxygen therapy for patients with COPD: current evidence and
178 the long-term oxygen treatment trial. *Chest* 2010;138(1):179-87. doi: 10.1378/chest.09-2555
179 [published Online First: 2010/07/08]
- 180 10. Khor YH, Goh NS, Glaspole I, et al. Exertional Desaturation and Prescription of Ambulatory Oxygen
181 Therapy in Interstitial Lung Disease. *Respir Care* 2019;64(3):299-306. doi:
182 10.4187/respcare.06334 [published Online First: 2018/11/01]
- 183 11. Hussain T, Saman HT, Yousaf Z. Identification of Exertional Hypoxia and Its Implications in SARS-CoV-
184 2 Pneumonia. *Am J Trop Med Hyg* 2020;103(4):1742-43. doi: 10.4269/ajtmh.20-1012 [published
185 Online First: 2020/08/28]

186

187

188 **Table 1:** Percentage of Inpatients with COVID-19 with Each Demographics and Clinical
 189 Variable Who Underwent Ambulatory Oximetry and Developed Need For Oxygen Therapies.

Characteristics	All Patients (n=531) %*	Nasal Cannula (n=70) %*	Advanced Oxygenation Therapy (n=34) %*
Ambulatory Hypoxia Present ^a	24.9	7.2	4.7
Age (years) ^b			
< 50	32.0	2.4	1.3
50-59	18.6	2.8	1.1
60-69	23.0	3.8	2.4
≥ 70	26.4	4.1	1.5
Gender			
Male	50.1	6.2	4.0
Female	49.9	7.0	2.4
Race and Ethnicity			
Non-Hispanic White	33.9	5.8	2.1
Hispanic or Latino	34.7	4.0	1.5
Black or African American	21.7	2.1	1.9
Other Races and ethnicities	9.8	1.3	0.9
BMI (kg/m ²) ^c			
< 24.9	21.8	3.0	1.5
25.0 - 29.9	29.2	3.4	1.3
30.0 - 39.9	30.5	3.8	1.7
≥ 40	10.0	2.1	1.5
Unmeasured	8.5	0.9	0.4
Admission D-Dimer (ng/mL)			
0-999	53.1	7.0	3.6
≥ 1000	5.8	0.8	0.8
Unmeasured	41.1	5.5	2.1
Admission Ferritin ^d (ng/mL)			
0 – 499	44.8	4.9	2.4
500 – 999	13.2	1.9	0.8
≥ 1000	11.1	2.1	1.7
Unmeasured	30.9	4.3	1.5
Admission CRP ^c (mg/L)			
0 – 99	55.6	6.8	3.2
100 – 199	13.4	2.6	1.3
≥ 200	4.5	0.9	0.8

Unmeasured	26.6	2.8	1.1
Charlson Score ^e			
0-2	43.5	3.4	2.1
3-5	31.6	4.7	2.3
≥ 6	24.9	5.1	2.1
Atrial Fibrillation	10.0	1.9	0.8
Coronary Artery Disease ^b	4.1	1.1	0.4
Congestive Heart Failure	12.2	2.4	1.1
Diabetes Mellitus	32.4	5.5	2.6
Connective Tissue Disorders	2.8	0.4	0.2
COPD	8.9	1.5	0.8
Liver Failure ^{c,e}	1.1	0.6	0.4
HIV	0.8	0.0	0.0
Hypertension	58.8	8.3	4.3
Leukemia or Lymphoma	9.0	1.7	0.9
Other Immunodeficiencies	0.8	0.4	0.0
Peripheral Artery Disease	3.6	0.8	0.0
Renal Disease ^b	19.0	3.6	1.5
Solid Tumor	4.0	0.4	0.4
Transplant ^b	5.1	1.3	0.6
^a p < 0.0001 for nasal cannula and advanced oxygenation therapy ^b p < 0.1 for nasal cannula ^c p < 0.1 for advanced oxygenation therapy ^d p < 0.05 for advanced oxygenation therapy ^e p < 0.05 for nasal cannula *All percent values are row percents relative to all patients (n=531)			

190

Table 2: Multiple Logistic and Poisson Regression Results for the Association of Ambulatory Hypoxia with the likelihood of Nasal Cannula or Advanced Oxygenation use in 531 Inpatients with COVID-19.

Characteristics	Nasal Cannula		Advanced Oxygenation	
	OR (95% CI)	p	IRR (95% CI)	p
Ambulatory Hypoxia Present	4.8 (2.8 - 8.4)	3×10^{-8}	7.7 (3.4 - 17.5)	8×10^{-7}
Age (years)				
< 50*	-	-	-	-
50-59	1.5 (0.6 - 3.6)	0.40	1.0 (0.3 - 3.2)	0.97
60-69	1.2 (0.4 - 3.1)	0.75	1.7 (0.5 - 6.2)	0.40
≥ 70	0.6 (0.2 - 1.8)	0.35	0.9 (0.2 - 4.1)	0.88
Gender				
Male	0.8 (0.5 - 1.4)	0.47	1.6 (0.7 - 3.6)	0.23
Female*	-	-	-	-
Race and Ethnicity				
Non-Hispanic White*	-	-	-	-
Hispanic or Latino	0.8 (0.4 - 1.7)	0.62	0.9 (0.3 - 2.5)	0.85
Black or African American	0.4 (0.2 - 0.9)	0.02	1.3 (0.5 - 3.4)	0.59
Other Races and ethnicities	1.0 (0.4 - 2.6)	0.98	2.1 (0.6 - 6.7)	0.23
BMI (kg/m ²)				
< 25.0*	-	-	-	-
25.0 - 29.9	1.0 (0.5 - 2.2)	0.95	0.7 (0.2 - 1.9)	0.48
30.0 - 39.9	1.0 (0.5 - 2.3)	0.91	0.8 (0.3 - 2.2)	0.64
≥ 40	2.3 (0.9 - 6.2)	0.10	2.6 (0.8 - 7.9)	0.10
Unmeasured	1.1 (0.3 - 3.4)	0.87	0.7 (0.1 - 3.5)	0.65
Admission CRP (mg/L)				
< 100*	-	-	-	-
100 – 199	-	-	1.9 (0.8 - 4.5)	0.96
≥ 200	-	-	1.7 (0.7 - 4.1)	0.81
Unmeasured	-	-	1.1 (0.4 - 2.9)	0.68
Admission Ferritin(ng/mL)				
< 500*	-	-	-	-
500 – 999	-	-	1.5 (0.5 - 4.7)	0.94
≥ 1000	-	-	0.9 (0.3 - 2.6)	0.28
Unmeasured	-	-	1.1 (0.3 - 3.5)	0.77
Charlson Score				

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

< 3*	-	-	-	-
3-5	2.4 (1.1 - 5.5)	0.03	1.4 (0.5 - 3.9)	0.55
≥ 6	4.6 (1.8 - 12.3)	0.002	1.4 (0.4 - 5.1)	0.63
*Denotes reference category				